Antiretroviral therapy with the integrase inhibitor raltegravir alters decay kinetics of HIV, significantly reducing the second phase
The DOI matches its Crossref record; 21 of the 22 references it cites were found in a registry or an index.
Abstract
OBJECTIVE: Raltegravir (MK-0518) belongs to the new class of HIV integrase inhibitors. To date, there have been no reports investigating the potential for differential effects on viral dynamics with integrase inhibitors relative to current antiretroviral drugs. METHODS: Patients in this phase II study (P004) were antiretroviral treatment naive. Part 1 of this study compared monotherapy with raltegravir (100 mg, 200 mg, 400 mg, or 600 mg twice daily) with placebo over 10 days. In part 2, patients were enrolled for 48 weeks of combination therapy, with randomization to one of the four dosages of raltegravir or to efavirenz, in addition to tenofovir and lamivudine. Mathematical models were used to investigate processes underlying viral dynamics. RESULTS: From day 15 through to day 57, individuals in the raltegravir arm were significantly more likely to have HIV RNA < 50 copies/ml (P < or = 0.047). Plasma viral loads were 70% lower at initiation of second-phase decay for individuals taking raltegravir than for those taking efavirenz (P < 0.0001). This challenges the current hypothesis that second-phase virus originates from infected long-lived cells, as an integrase inhibitor should not impact on viral production from this cell population. Mathematical modeling supported two hypotheses as consistent with these observations: (i) that second-phase virus arises from cells newly infected by long-lived infected cells and (2) that it arises from activation of latently infected cells with full-length unintegrated HIV DNA. CONCLUSIONS: These observations challenge the current understanding of HIV-1 turnover and compartmentalization. They also indicate the promise of this new integrase inhibitor raltegravir.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Therefore, it is not surprising that 24 years transpired from the discovery of HIV-1 before the first IN strand transfer inhibitor (INSTI), raltegravir, became available in clinical practice146.”
From Structure and function of retroviral integrase (2022) · cites this paper as [146]
Citations
Cites
Rapid turnover of plasma virions and CD4 lymphocytes in HIV-1 infection
Ho, D. D., Neumann, A. U., Perelson, A. S., Chen, W., Leonard, J. M., & Markowitz, M. (1995) · Nature · doi:10.1038/373123a0 · Cited by 4,267 · cited 1×
“It is generally believed that virus observed during the first-phase decay arises from productively infected CD4 T cells, and that this phase of viral decay tracks their death [9,10].”
BackgroundViral dynamics in human immunodeficiency virus type 1 infection
Wei, X., Ghosh, S. K., Taylor, M. E., Johnson, V. A., Emini, E. A., Deutsch, P., Lifson, J. D., Bonhoeffer, S., Nowak, M. A., Hahn, B. H., et al. (1995) · Nature · doi:10.1038/373117a0 · Cited by 3,260 · cited 1×
“It is generally believed that virus observed during the first-phase decay arises from productively infected CD4 T cells, and that this phase of viral decay tracks their death [9,10].”
BackgroundFinzi, D., Blankson, J., Siliciano, J. D., Margolick, J. B., Chadwick, K., Pierson, T., Smith, K., Lisziewicz, J., Lori, F., Flexner, C., et al. (1999) · Nature Medicine · doi:10.1038/8394 · Cited by 2,119 · cited 2×
“Regardless of whether ongoing infection or the slow turnover of resting CD4 T cells is primarily responsible, the latent pool decreases slowly under standard ART, with a half-life of anywhere between 6 months [16,17] and 44 months [18].”
BackgroundPresence of an inducible HIV-1 latent reservoir during highly active antiretroviral therapy
Chun, T.-W., Stuyver, L., Mizell, S. B., Ehler, L. A., Mican, J. A. M., Baseler, M., Lloyd, A. L., Nowak, M. A., & Fauci, A. S. (1997) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.94.24.13193 · Cited by 1,977 · cited 5×
“The high levels under ART of unintegrated HIV DNA in resting CD4 T cells [13], and proviral sequence evolution in individuals with undetectable HIV RNA [16], suggest that there is persistent viral replication even in the presence of seemingly successful ART.”
BackgroundInfluentialDecay characteristics of HIV-1-infected compartments during combination therapy
Perelson, A. S., Essunger, P., Cao, Y., Vesanen, M., Hurley, A., Saksela, K., Markowitz, M., & Ho, D. D. (1997) · Nature · doi:10.1038/387188a0 · Cited by 1,880 · cited 6×
“Estimates were made on the length of treatment needed before this could be achieved [6].”
BackgroundResultInfluentialInhibitors of Strand Transfer That Prevent Integration and Inhibit HIV-1 Replication in Cells
Hazuda, D. J., Felock, P., Witmer, M., Wolfe, A., Stillmock, K., Grobler, J. A., Espeseth, A., Gabryelski, L., Schleif, W., Blau, C., et al. (2000) · Science · doi:10.1126/science.287.5453.646 · Cited by 1,131 · cited 1×
“Under each of these models, there may be an increase in aborted HIV DNA integration and a resulting rise in extrachromosomal viral DNA in circular forms containing one or two long terminal repeats (2LTR circles), as observed in vitro [2].”
BackgroundSelf-citationChun, T.-W., Engel, D., Berrey, M. M., Shea, T., Corey, L., & Fauci, A. S. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.15.8869 · Cited by 846 · cited 1×
“This component is established early in infection [15] and consists of both unintegrated and integrated HIV DNA even under ART [13].”
BackgroundQuantifying Residual HIV-1 Replication in Patients Receiving Combination Antiretroviral Therapy
Zhang, L., Ramratnam, B., Tenner-Racz, K., He, Y., Vesanen, M., Lewin, S., Talal, A., Racz, P., Perelson, A. S., Korber, B. T., et al. (1999) · New England Journal of Medicine · doi:10.1056/nejm199905273402101 · Cited by 807 · cited 3×
“Regardless of whether ongoing infection or the slow turnover of resting CD4 T cells is primarily responsible, the latent pool decreases slowly under standard ART, with a half-life of anywhere between 6 months [16,17] and 44 months [18].”
BackgroundGrinsztejn, B., Nguyen, B.-Y., Katlama, C., Gatell, J. M., Lazzarin, A., Vittecoq, D., Gonzalez, C. J., Chen, J., Harvey, C. M., & Isaacs, R. D. (2007) · The Lancet · doi:10.1016/s0140-6736(07)60597-2 · Cited by 574 · cited 2×
“Ten-day monotherapy trials investigating dosing levels and tolerability of integrase inhibitors have been reported [1,3], and preliminary results from phase II studies suggest that this new class of drugs can be effective in controlling HIV replication even in individuals infected with multiclass drug-resistant virus…”
BackgroundSelf-citationRamratnam, B., Mittler, J. E., Zhang, L., Boden, D., Hurley, A., Fang, F., Macken, C. A., Perelson, A. S., Markowitz, M., & Ho, D. D. (2000) · Nature Medicine · doi:10.1038/71577 · Cited by 452 · cited 2×
“The rate of decrease is dependent on residual viral replication [17], and hence drugs like raltegravir that increase the effectiveness of ART, especially for viral components such as unintegrated HIV DNA that are immune to current drugs, may improve this rate of decay.”
Background
Cited by
Cohen, M. S., Shaw, G. M., McMichael, A. J., & Haynes, B. F. (2011) · New England Journal of Medicine · doi:10.1056/nejmra1011874 · Cited by 660
Lennox, J. L., DeJesus, E., Lazzarin, A., Pollard, R. B., Madruga, J. V. R., Berger, D. S., Zhao, J., Xu, X., Williams-Diaz, A., Rodgers, A. J., et al. (2009) · The Lancet · doi:10.1016/s0140-6736(09)60918-1 · Cited by 625
Self-citationChrist, F., Voet, A., Marchand, A., Nicolet, S., Desimmie, B. A., Marchand, D., Bardiot, D., Van der Veken, N. J., Van Remoortel, B., Strelkov, S. V., et al. (2010) · Nature Chemical Biology · doi:10.1038/nchembio.370 · Cited by 479
van Lunzen, J., Maggiolo, F., Arribas, J. R., Rakhmanova, A., Yeni, P., Young, B., Rockstroh, J. K., Almond, S., Song, I., Brothers, C., et al. (2012) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(11)70290-0 · Cited by 301
Modeling HIV persistence, the latent reservoir, and viral blips
Rong, L., & Perelson, A. S. (2009) · Journal of Theoretical Biology · doi:10.1016/j.jtbi.2009.06.011 · Cited by 245
“This may explain that patients taking a raltegravir-based HAART regimen have a faster time to suppression of viremia than patients taking a HAART regimen based on the RT inhibitor efavirenz (Markowitz et al., 2007; Murray et al., 2007).”
Method
Metadata
- Authors
- Murray, J. M., Emery, S., Kelleher, A. D., Law, M., Chen, J., Hazuda, D. J., Nguyen, B.-Y. T., Teppler, H., & Cooper, D. A.
- Affiliations
- UNSW Sydney (AU)
- Merck & Co., Inc., Rahway, NJ, USA (United States) (US)
- Corresponding author
- Murray, John M
- ORCID
- Venue
- AIDS
- Published
- 2007-11
- Volume
- 21
- Issue
- 17
- Pages
- 2315-2321
- ISSN
- 0269-9370 (ISSN-L)
- OpenAlex
- W2028179886
- Cited by
- 187
- References
- 22
- Citations by year
- 2024: 1 · 2023: 2 · 2022: 7 · 2021: 3 · 2020: 3 · 2019: 6 · 2018: 6 · 2017: 7 · 2016: 9 · 2015: 6 · 2014: 14 · 2013: 17 · 2012: 19
- FWCI
- 7.71
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- AIDS (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Immunology and Microbiology › Virology › HIV Research and Treatment
- Health Sciences › Medicine › Infectious Diseases › HIV/AIDS drug development and treatment
- Health Sciences › Medicine › Infectious Diseases › HIV/AIDS Research and Interventions
- Keywords
- raltegravir, HIV integrase inhibitors, viral load dynamics, HIV latency, viral compartmentalization, efavirenz, tenofovir, lamivudine, antiretroviral-naive patients, mathematical modeling of viral dynamics
- MeSH terms
- Tenofovir, Raltegravir Potassium, Adenine, Alkynes, Cyclopropanes, Drug Administration Schedule, Drug Therapy, Combination, HIV, Humans, Organic Chemicals, Pyrrolidinones, RNA, Viral, Time Factors, Virus Replication, HIV Infections, Linear Models, Virus Integration, Virus Latency, Statistics, Nonparametric, Lamivudine, Anti-HIV Agents, HIV Integrase Inhibitors, Viral Load, Benzoxazines, Organophosphonates
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Antiretroviral therapy with the integrase inhibitor raltegravir alters decay kinetics of HIV, significantly reducing the second phase. https://app.cochat.ai/papers/10.1097/qad.0b013e3282f12377
- The paper
- Murray, J. M., Emery, S., Kelleher, A. D., Law, M., Chen, J., Hazuda, D. J., Nguyen, B.-Y. T., Teppler, H., & Cooper, D. A. (2007). Antiretroviral therapy with the integrase inhibitor raltegravir alters decay kinetics of HIV, significantly reducing the second phase. AIDS. https://doi.org/10.1097/qad.0b013e3282f12377
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.